Interview with Karl Nikitsch, Menarini Austria
Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today reflects the vision you had for the company in Austria…
Address: Vorgartenstraße 206b
A-1020 Wien
,Austria
Tel: +43 (0)1 610 30 – 0
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.
Cardiovascular and metabolic disorders
Through our pharmaceutical research and development efforts, we are developing innovative solutions and medications that can help people around the world living with diabetes, obesity, thrombosis and other chronic and potentially life-threatening conditions.
Immunology
Building upon our long-standing commitment to immunology, we continue to deliver new options to combat complex conditions, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis. Our rich heritage of innovation in biological research and medicines has allowed us to expand to oral and inhaled medicines for immunologic and pulmonary diseases.
Infectious diseases and vaccines
With a goal to improve public health by fighting infectious diseases worldwide, we are dedicated to delivering treatments for people living with HIV/AIDS, hepatitis C, tuberculosis, and other infectious diseases. Recently, we entered the field of prevention with the acquisition of Crucell, a company that develops vaccines and antibodies. As a result, we have a number of marketed vaccines and have furthered our pipeline based on Crucell’s unique technologies.
Neuroscience
With a longstanding, continued commitment to neuroscience, our vision is to reduce the burden, disability and devastation caused by serious neuropsychiatric diseases and pain conditions and restore hope for patients. Our areas of focus include: Neurology, which includes Alzheimer’s disease; psychiatry, focused on mood disorders, such as bipolar disease and major depressive disorder, and schizophrenia; and pain, where we have particular interest in chronic pain states and neuropathic pain.
Oncology
Through groundbreaking research and innovative partnerships, we aim to transform cancer into a preventable, chronic or curable disease. Our goal is to deliver diagnostic and therapeutic options that prolong and improve patients’ lives. We are focused on key cancer types, including ovarian cancer, hematologic malignancies, prostate cancer and lung cancers. We are dedicated to helping realize the promise of winning the “war on cancer.”
Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today reflects the vision you had for the company in Austria…
Can you give our readers a snapshot of Austroplant’s scope of activities and its structure in Austria and the central European market? Austroplant/Dr Peithner belongs to the Schwabe Group, the…
Dr Prchla, you have been heading Merck’s Austrian subsidiary over the past eighteen months. What do you see as the key strengths of your company today? Mirroring the company’s structure,…
Just like other European countries, Austria is in the search for meaningful savings in healthcare. Austria’s increasingly price sensitive pharma market is seeing the rise of generic medicines gaining market…
Whereas most General Managers are exposed to different countries during their professional career, you have chosen to dedicate yours to the Austrian market. What is it in this country so…
You have been General Secretary of PHARMIG since 2004 and have witnessed the market’s development over the past 8 years. What have been the most important changes since you started…
See our Cookie Privacy Policy Here